News archive for Structural biology and drug discovery
As part of a consortium lead by the EU-Openscreen head office with the overall goal to improve the services offered by EU-Openscreen, the Brenk group has got funding to work on Ribotacs. Ribotacs are small molecules that selectively bind RNAs and a RNAse and thus lead targeted RNA degradation. We look forward to a succesfull collaboration.
- April 2025 (1)
- March 2025 (1)
- December 2024 (1)
- August 2024 (1)
- May 2024 (1)
- February 2024 (1)
- January 2024 (1)
- July 2023 (1)
- September 2022 (1)